September 25, 2023
MC2 Therapeutics gets option rights for oral drug candidate for Hidradenitis Suppurativa
MC2 Therapeutics has acquired option rights from Regranion, LLC to exclusively license Regranion’s RGRN-305 for the treatment of all human…